Most advanced
Droplet Microfluidic Device
High-Throughput Antibody Discovery
Secretome-based – functional
With ModaFlowTM, revolutionize antibody discovery by enabling high-throughput screening of millions of individual cells in picoliter droplets with unrivalled precision. Reduce costs, enhances efficiency, and shortens discovery timelines.
See moreHigh-Throughput spheroids and organoids for drug testing
Standardized – automated - little starting material
The production of spheroids and organoids with OneFlowTM enables rapid, consistent, and scalable production of 3D cell cultures for drug screening, regenerative medicine, and cancer research. It favors cell aggregation, cell-cell interactions and ensures uniform spheroid size, enhancing reproducibility and reliability in experiments. Microfluidic droplet-based spheroid generation drastically reduces processing time, minimizes cell and reagent consumption, and allows for high-throughput screening, accelerating biomedical research and therapeutic development.
See moreKey numbers
10M+
Cells/hour
Offering advanced capabilities in high-throughput encapsulation of biological materials from single cells to spheroids.
0%
Waste
With zero dead volume, our instrument allows processing 100% of the injected sample, making it particularly interesting for rare materials.
100%
Flexible
A highly flexible platform to run tens of various assays and workflows. The limit is your imagination.
5
Colors
Full spectrum available for multiplex fluorescence screening.
As specialists in droplet microfluidic screening, we evaluated multiple technologies and identified the ModaFlow platform as the most efficient in terms of sample economy, usability, and reproducibility. The instrument is highly intuitive to operate, and it consistently delivers reliable, high‑quality results.
To date, we have successfully applied the system for hydrogel droplet generation within the context of compound library screening.
Furthermore, the customer service and application support teams have been very responsive, knowledgeable, and quick to address all our questions. Overall, we are extremely satisfied with the platform and the support provided.
Evelien Mathieu
PhD, Senior Scientist Lead Characterization
Sanofi
At Cellistic, we are committed to advance allogeneic cell therapy using iPSC. Our iPSC allogeneic cell therapy platforms Pulse and Echo are build using state of the art technology. To advance our capabilities further we are thrilled to work with LiveDrop’s advanced microfluidic technology. This technology has several benefits and perfectly aligns with our mission to make cell therapies more accessible and affordable. By enhancing cell line development precision and accelerating manufacturing processes, we are reinforcing our commitment to delivering cutting-edge cell therapy solutions with greater efficiency.
Stefan Braam
Founder and CTO
Cellistic
Droplet microfluidics integrated with LiveDrop’s advanced bioassays is revolutionizing immunology research. These tools enable high-throughput B-cell screening (sequencing?), monoclonal antibody discovery, and single-cell antibody response studies with unmatched precision. A game-changer technology to support innovation in Life Sciences. By rapidly screening plasma cells and Fc receptor interactions, LiveDrop drive breakthroughs in autoimmune and allergy therapies, transforming our understanding of human immunity.
Adrien Boes
PhD
CER Group, Belgium
